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Abstract     
The present paper deals with an improved synthesis of two molecular hybrids of AMPA and KA, 
compounds CIP-A and CIP-B, and their transformation into CIOP-A and CIOP-B, the 
corresponding amido derivatives. Exploiting the continuous-flow technology, a significant 
improvement in the synthesis of the glutamate agonists CIP-A and CIP-B was accomplished, in 
terms of overall yield, time, and excess of ethyl chlorooximinoacetate. Moreover, we find out the 
HPLC conditions suitable to separate, at a preparative level, the three intermediates formed in the 
1,3-dipolar cycloaddition step. 
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Introduction  
 
The acidic amino acid neurotransmitter L-glutamate (Glu) plays a pivotal role in the excitatory 
pathways of the mammalian central nervous system (CNS).1,2 Once released from the 
presynaptic neurons into the glutamatergic synaptic cleft, Glu activates two main classes of 
receptors: G-protein-coupled metabotropic Glu receptors (mGluRs) and ligand-gated ionotropic 
Glu receptors (iGluRs). The iGluRs are the major players in the fast neuronal signaling and 
represent a potential therapeutic target for the treatment of a number of neurological and 
psychiatric disorders, i.e. chronic pain, stroke, epilepsy, drug addiction, schizophrenia, and 
Alzheimer, Huntington and Parkinson diseases.3-7 
On the basis of the agonist selectivity, iGluRs have been subclassified into N-methyl-D-
aspartate (NMDA) receptors, 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionate (AMPA) 
receptors, and kainate (KA) receptors.1,2 The functional ion channel is composed of four 
subunits, which can assemble either homomerically or heteromerically. A total of seven NMDA 
subunits (GluN1, GluN2A-D and GluN3A-B), four AMPA subunits (GluA1-4), and five KA 
subunits (GluK1-5) have been cloned and characterized.2 
In the past, we have designed compounds CIP-A, CIP-B, HIP-A, and HIP-B (Figure 1) as 
molecular hybrids of AMPA and KA. In red is highlighted the structural part representing the 
skeleton of glutamic acid, homoglutamic acid (CIP-B) or aspartic acid (HIP-A).8-11 
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Figure 1. Structure of (S)-AMPA, KA and their molecular hybrids. 
 
As expected, compound CIP-A turned out to be a potent agonist at both AMPA and KA 
receptors without any activity at NMDA receptors.8,9 The eutomer of CIP-A was characterized 
by the S configuration at the amino acidic stereogenic center. On the contrary, both HIP-A and 
HIP-B turned out to be inactive at metabotropic and ionotropic glutamate receptors whereas they 
were provided with an interesting inhibitory activity at glutamate transporters.12-15 In parallel, we 
carried out a detailed investigation on the structure-activity relationships of these rigidified 
aspartate-glutamate analogues to find out selective iGluR ligands. The bicyclic structure was 
either simplified into monocyclic derivatives or was conserved and the chain connecting the 
amino acidic moiety and the distal acidic group was elongated or shortened. In such a way we 
were able to modulate their pharmacological profile on passing from agonists to antagonists or to 
generate a remarkable selectivity for one of the three iGluRs.16-30 In the planned derivatives, we 
always preserved the aminoacid moiety because the X-ray structural analyses of the iGluRs 
bilobular ligand-binding core in complex with agonists or antagonists evidenced the crucial role 
played by such a group.31 In a recent paper,32 it was described a series of derivatives generated 
by the incorporation of the structural elements of both kainic acid and neodysiherbaine A 
(neoDH), two naturally occurring pro-convulsant agents. Surprisingly, some of them, e.g. 
derivative IKM-159, are characterized by the presence in their structure of the -carboxylate 
amido group (Figure 2) and are those provided with a potent AMPA-selective antagonistic 
activity.32 On this ground, we designed the corresponding analogues of CIP-A and CIP-B in 
order to test their pharmacological profile and their selectivity versus AMPA receptor subtypes.  
The present paper deals with an improved synthesis of CIP-A and CIP-B and their 
transformation into CIOP-A and CIOP-B, the corresponding amido derivatives (Figure 2).  
 
 
Figure 2. Structures of model and target compounds. 
 
 
Results and Discussion    
 
According to a literature report,9 the synthesis of CIP-A and CIP-B, as pure enantiomers, has 
been accomplished as depicted in Scheme 1. 
 
 
 
Scheme 1. Previously reported synthesis of CIP-A and CIP-B.9 
 
The major drawbacks associated to the described procedure9 are: i) the low reactivity of 
dipolarophile 1 and ii) the failure to separate cycloadduct 3 from 4 by column chromatography. 
For such a reason, the mixture was transformed into the corresponding secondary amines 5 and 6 
which were separated by column chromatography and then reconverted into the N-Boc 
derivatives 3 and 4, respectively.  
In order to overcome the first drawback, we decided to investigate the feasibility of the 
cycloaddition reaction with the flow technology by using a procedure previously applied to 
similar pericyclic reactions.33,34 As shown in scheme 2, an ethyl acetate solution of N-Boc-3,4-
dehydro-L-proline methyl ester 1, prepared under flow conditions as previously reported,35 and 
ethyl chlorooximinoacetate were mixed and delivered to a glass column filled with solid K2CO3 
heated at 90 °C. The desired cycloadducts were obtained in good yield (70%) in only 10 min and 
a slight excess of chloroxime. This result represents a significant improvement over the above 
described conventional methodology because the reaction time was considerably reduced (from 
6 days to 10 min) and the overall yield improved (from 56% to 70%).  
 
 
Scheme 2.The cycloaddition reaction in a continuous flow reactor. 
 
The second drawback, due to the incapability to split with a silica gel column 
chromatography the mixture of cycloadducts 2, 3, and 4, was explored by making use of a 
preparative HPLC. After a substantial number of attempts, we found out the conditions suitable 
to separate the cycloadducts at a preparative level. An excellent separation (see experimental 
section) was obtained with the amylose tris-(5-chloro-2-methyl-phenyl-carbamate) stationary 
phase, allowing us to collect a substantial amount of each stereoisomer. The cycloaddition step 
yielded intermediates 2:3:4 in the ratio 40:14:46. 
Cycloadducts 2 and 4 were then oxidized with a catalytic amount of hydrated ruthenium (IV) 
oxide and a 10% aqueous solution of sodium periodate in a biphasic system water/ethyl acetate 
to give intermediate 7 and 8, respectively. Their stereochemistry was secured by 1H NMR. As a 
matter of fact, derivative 7 shows proton 3a at 4.53 as a doublet (J = 9.3 Hz), whereas the same 
proton in derivative 8 resonates at 4.10 as a doublet of doublet (J = 1.3, 10.4 Hz). Intermediates 7 
and 8 were treated with an aqueous 6N HCl solution, according to the procedure described for 
the synthesis of IKM 159 (Scheme 3).36 
 
Scheme 3. Reagents and conditions: a: RuO2*H2O, NaIO4, H2O/AcOEt; b: HCl 6N, Δ. 
 
Unfortunately, we obtained a 1:2 unsplitable mixture of CIOP-B and 9 or CIOP-A and 10. 
The hydroxynitrile side-products 9 and 10 derived from the low stability of the isoxazoline ring 
under aqueous acidic conditions. Therefore, we decided to remove thenitrogen protecting group 
by treating derivatives 7 and 8 with an excess of trifluoroacetic acid; amides 11 and 12 were 
obtained in good yield (Scheme 4). 
 
 
Scheme 4. Reagents and conditions: a: 30% TFA/CH2Cl2; b: K2CO3, H2O. 
 
Final compounds CIOP-B and CIOP-A were obtained, in quantitative yield, through the 
alkaline hydrolysis of the two ester groups under mild conditions, i.e. 2.2 equivalent of an 
aqueous K2CO3 solution. Using harsher basic condition, such as an aqueous NaOH solution, we 
observed a substantial degradation of the cycloadducts.  
 
 
Conclusions 
 
We have accomplished a significant improvement in the synthesis of glutamate agonists CIP-A 
and CIP-B in terms of overall yield, time, and excess of ethyl chlorooximinoacetate. 
Furthermore, we find out the HPLC conditions suitable to separate, at a preparative level, the 
three cycloadducts 2, 3, and 4. In such a way, we avoided the lengthy procedure based on the 
transformation of the unsplittable mixture of derivative 3 and 4 into the corresponding secondary 
amines 5 and 6, their separation by a silica gel column chromatography and then their 
reconvertion into the N-Boc derivatives 3 and 4. Furthermore, the two regioisomers 2 and 4 were 
transformed into final derivatives CIOP-B and CIOP-A, respectively, via an oxidation step, 
removal of the N-Boc protecting group and a careful hydrolysis of the two ester groups. The 
biological results of novel derivatives CIOP-A and CIOP-B will challenge the involvement of 
the amino acid moiety in determining the binding to the active site of the ionotropic glutamate 
receptors. These data will be reported in due course. 
 
 
Experimental Section 
 
General. All reagents were purchased from Sigma. 1H NMR and 13C NMR spectra were 
recorded with a Varian Mercury 300 (300 MHz) spectrometer. Chemical shifts (δ) are expressed 
in ppm, and coupling constants (J) are expressed in Hz. Rotary power determinations were 
carried out using a Jasco P-1010 spectropolarimeter, coupled with a Haake N3-B thermostat. 
TLC analyses were performed on commercial silica gel 60 F254 aluminum sheets; spots were 
further evidenced by spraying with a dilute alkaline potassium permanganate solution or 
ninhydrin. MS analyses were performed on a Varian 320-MS triple quadrupole mass 
spectrometer with ESI source. Microanalyses (C, H, N) of new compounds were within ±0.4% of 
theoretical values. HPLC analyses were performed with a Jasco PU-980 pump equipped with a 
UV–vis detector Jasco UV-975 (wavelength: 220 nm) and Phenomenex Lux Amylose-2 column 
(4.6 × 150 mm). Preparative HPLC was performed with a 1525 Extended Flow Binary HPLC 
Pump, equipped with a Waters 2489 UV-vis detector and a Phenomenex Lux Amylose-2 column 
(21.2 × 150 mm) at a flow rate of 15 mL/min. The continuous-ﬂow cycloaddition was performed 
using a R2+/R4 ﬂow reactor, commercially available from Vapourtec equipped with Omniﬁt 
glass column. 
 
 (3aR,6R,6aS)-5-tert-Butyl 3-ethyl 6-methyl 3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazole-
3,5,6-tricarboxylate (2), (3aS,6S,6aR)-5-tert-butyl 3-ethyl 6-methyl 3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazole-3,5,6-tricarboxylate (3), and (3aS,4S,6aR)-5-tert-butyl 3-
ethyl 4-methyl 3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazole-3,4,5-tricarboxylate (4). A 0.25 
M solution of methyl N-Boc-3,4-dehydro-L-proline methyl ester (1.0 mmol) in EtOAc (4 mL) 
and a 0.37 M solution of ethyl chlorooximinoacetate (1.5 mmol) in EtOAc (4 mL) were 
prepared. The two reactant streams were mixed using a simple T-piece and delivered to a glass 
column (6.6 mm i.d.× 100 mm length) filled with K2CO3 (4.0 mmol, 540 mg) heated at 90 °C at 
a total flow rate of 0.1mL min-1, equating to a residence time of about 10 min. A 100 psi 
backpressure regulator was applied to the system. The solvent was evaporated, and the crude 
material was purified by silica gel column chromatography (cyclohexane–EtOAc 7:3) to yield 
the mixture of cycloadducts 2, 3, 4 in 70% overall yield. Analytical HPLC condition: 
wavelength, 220 nm; eluent, n-hexane–isopropanol (8:2). Retention times: 4, 7.51 min.; 2, 13.01 
min.; 3, 16.77 min. 
 (3aR,6S,6aS)-5-tert-Butyl 3-ethyl 6-methyl 3a,4,6,6a-tetrahydro-4-oxopyrrolo[3,4-d]-
isoxazole-3,5,6-tricarboxylate (7). To a magnetically stirred 10% aqueous solution of NaIO4 
(2.38 g, 11.4 mmol) was added RuO2*H2O (21 mg). The mixture was immediately poured into a 
solution of cycloadduct 2 (960 mg, 2.84 mmol) in EtOAc (27 mL) and the resulting suspension 
was vigorously stirred at room temperature for 24h. The black solid was removed by filtration 
under vacuum through a short Celite pad, and the organic layer was separated and treated with 2-
propanol (2 mL). The organic solution was dried over anhydrous Na2SO4, the solvent removed 
under vacuum, and the residue was column chromatographed (cyclohexane–EtOAc 7:3) to give 
130 mg of the desired product 7 and 560 mg of the unreacted starting material 2. Yield based on 
recovered starting material: 75%. Colorless oil; []D20 − 27.3 (c 0.56, CHCl3); Rf 0.25 
(Cyclohexane–EtOAc, 7:3). 1H NMR (300 MHz, CDCl3):  1.38 (t, 3H, J 7.0); 1.45 (s, 9H); 3.82 
(s, 3H); 4.36 (q, 2H, J 7.0); 4.53 (d, 1H, J 9.3); 4.91 (s, 1H;); 5.23 (d, 1H, J 9.3). 13C NMR (75 
MHz, CDCl3): 14.2, 28.0, 53.6, 55.2, 63.1, 64.7, 82.0, 85.4, 148.7, 149.3, 158.5, 165.0, 168.8. 
MS: 357.1 [M+H]+. Anal. Calcd for C15H20N2O8: C, 50.24; H, 5.79; N, 7.86. Found: C 50.37, H 
5.76, N 7.75. 
 (3aS,4S,6aR)-5-tert-Butyl 3-ethyl 4-methyl 3a,4,6,6a-tetrahydro-6-oxopyrrolo[3,4-d]-
isoxazole-3,4,5-tricarboxylate (8). To a magnetically stirred 10% aqueous solution of NaIO4 
(2.43 g, 11.4 mmol) was added RuO2*H2O (21 mg). The mixture was immediately poured into a 
solution of cycloadduct 4 (970 mg, 2.84 mmol) in EtOAc (27 mL) and the resulting suspension 
was vigorously stirred at room temperature for 24h. The black solid was removed by filtration 
under vacuum through a short Celite pad, and the organic layer was separated and treated with 2-
propanol (2 mL). The organic solution was dried over anhydrous Na2SO4, the solvent removed 
under vacuum, and the residue was column chromatographed (cyclohexane–EtOAc 7:3) to give 
140 mg of the desired product 8 and 590 mg of the unreacted starting material 4. Yield based on 
recovered starting material: 75%. Colorless oil; []D20 − 176.0 (c 0.56, CHCl3); Rf 0.25 
(Cyclohexane–EtOAc, 7:3). 1H NMR (300 MHz, CDCl3):  1.38 (t, 3H, J 7.0); 1.45 (s, 9H); 3.82 
(s, 3H); 4.10 (dd, 1H, J 1.3, 10.4); 4.33−4.44 (m, 2H); 4.90 (d, 1H, J 1.3); 5.37 (d, 1H, J 10.4). 
13C NMR (75 MHz, CDCl3):  14.2, 28.0, 47.4, 53.6, 59.8, 63.2, 83.0, 85.5, 148.7, 150.2, 159.3, 
166.8, 170.4. MS: 357.1 [M+H]+. Anal. Calcd for C15H20N2O8: C, 50.24; H, 5.79; N, 7.86. 
Found: C 50.33, H 5.78, N 7.72. 
 (3aR,6S,6aS)-3-Ethyl 6-methyl 4,5,6,6a-tetrahydro-4-oxo-3aH-pyrrolo[3,4-d]isoxazole-3,6-
dicarboxylate (11). Compound 7 (130 mg, 0.37 mmol) was treated with 1 mL of a 30% CH2Cl2 
solution of triﬂuoroacetic acid at 0 °C. The solution was stirred at room temperature for 4 h. The 
volatiles were removed under vacuum and the residue was purified by flash chromatography to 
yield 65 mg (70% yield) of the desired product 11 as a colorless oil that was immediately used in 
the next synthetic step. Rf 0.6 (EtOAc). 
1H NMR (300 MHz, CDCl3): 1.40 (t, 3H, J 7.0); 3.82 (s, 
3H); 4.40 (q, 1H, J 7.0); 4.40 (d, 1H, J 9.3); 4.50 (s, 1H); 5.60 (d, 1H, J 9.3); 6.82 (bs, 1H). 13C 
NMR (75 MHz, CDCl3):  14.3, 53.6, 55.3, 63.2, 64.9, 85.4, 149.4, 163.9, 165.0, 168.9. MS: 
257.1 [M+H]+. Anal. Calcd for C10H12N2O6: C, 46.88; H, 4.72; N, 10.93. Found: C 47.00, H 
4.53, N 10.80. 
 (3aS,4S,6aR)-3-Ethyl 4-methyl 4,5,6,6a-tetrahydro-6-oxo-3aH-pyrrolo[3,4-d]isoxazole-3,4-
dicarboxylate (12). Compound 8 (140 mg, 0.40 mmol) was treated with 1 mL of a 30% CH2Cl2 
solution of triﬂuoroacetic acid at 0 °C. The solution was stirred at room temperature for 4 h. The 
volatiles were removed under vacuum and the residue was purified by flash chromatography to 
yield 75 mg (75% yield) of the desired product 12 as a colorless oil that was immediately used in 
the next synthetic step. Rf 0.6 (EtOAc). 
1H NMR (300 MHz, CDCl3):  1.40 (t, 3H, J 7.3); 3.82 
(s, 3H); 4.35-4.44 (m, 2H); 4.46 (dd, 1H, J 1.2, 10.2); 4.55 (d, 1H, J 1.2); 5.32 (d, 1H, J 10.2); 
7.50 (bs, 1H).13C NMR (75 MHz, CDCl3):  14.1, 47.5, 53.7, 59.7, 63.3, 85.6, 150.3, 163.5, 
166.9, 170.5. MS: 257.1 [M+H]+. Anal. Calcd for C10H12N2O6: C, 46.88; H, 4.72; N, 10.93. 
Found: C 47.08, H 4.50, N 10.78. 
 (3aR,6S,6aS)-4,5,6,6a-Tetrahydro-4-oxo-3aH-pyrrolo[3,4-d]isoxazole-3,6-dicarboxylic acid 
(CIOP-B). Compound 9 (60 mg, 0.23 mmol) was suspended in bi-distilled water and K2CO3 (71 
mg, 0.52) was added. The reaction mixture was stirred at room temperature for 16h. The mixture 
was made acidic (pH 2) with 1N aqueous HCl and the solvent was removed under reduced 
pressure. The residue was taken up with acetone and filtered. The solvent was removed under 
reduced pressure to give CIOP-B (50 mg, 0.23 mmol) as a white solid.[]D20 + 2.0 (c 0.41, 
H2O). 
1H NMR (300 MHz, D2O):  4.38 (d, 1H, J 1.1); 4.42 (d, 1H, J 9.1); 5.47 (dd, 1H, J 1.1, 
9.1). 13C NMR (75 MHz, D2O):  55.5, 63.7, 86.7, 153.1, 163.9, 173.1, 174.4. MS: 212.9 
[M−H]−. Anal. Calcd for C7H6N2O6: C, 39.26; H, 2.82; N, 13.08. Found: C, 39.06; H, 2.87; N, 
13.01. 
 (3aS,4S,6aR)-4,5,6,6a-Tetrahydro-6-oxo-3aH-pyrrolo[3,4-d]isoxazole-3,4-dicarboxylic acid 
(CIOP-A). Compound 10 (70 mg, 0.27 mmol) was suspended in bi-distilled water and K2CO3 
(83 mg, 0.60) was added. The reaction mixture was stirred at room temperature for 16 h. The 
mixture was made acidic (pH 2) with 1N aqueous HCl and the solvent was removed under 
reduced pressure. The residue was taken up with acetone and filtered. The solvent was removed 
under reduced pressure to give compound CIOP-A (58 mg, 0.27 mmol) as a white solid.[]D20 − 
189.8 (c 0.42, H2O). 
1H NMR (300 MHz, D2O):  4.42 (dd, 1H, J 1.5, 9.7); 4.53 (d, 1H, J 1.5); 
5.33 (d, 1H, J 9.7). 13C NMR (75 MHz, D2O):  51.5, 58.0, 82.5, 155.1, 163.2, 174.1, 174.6. MS: 
212.8 [M−H]−. Anal. Calcd for C7H6N2O6: C, 39.26; H, 2.82; N, 13.08. Found: C, 39.64; H, 
2.95; N, 12.86. 
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